| 摘要 |
The present invention provides cytotoxic Epstein-Barr virus (EBV) T-cell epitopes derived from EBV structural antigens. Preferred epitopes include YLLEMLWRL (SEQ ID NO: 1), YFLEILWGL (SEQ ID NO: 32), YLLEILWRL (SEQ ID NO: 33), YLQQNWWTL (SEQ ID NO: 6), LLLALLFWL (SEQ ID NO: 2), LLVDLLWLL (SEQ ID NO: 3), LLLIALWNL (SEQ ID NO: 4), WLLLFLAIL (SEQ ID NO: 5), TLLVDLLWL (SEQ ID NO: 7), LLWLLLFLA (SEQ ID NO: 8), ILLIIALYL (SEQ ID NO: 9), VLFIFGCLL (SEQ ID NO: 10), RLGATIWQL (SEQ ID NO: 11), ILYFIAFAL (SEQ ID NO: 15), SLVIVTTFV (SEQ ID NO: 17), LMIIPLINV (SEQ ID NO: 20), TLFIGSHVV (SEQ ID NO: 24), LIPETVPYI (SEQ ID NO: 26), VLQWASLAV (SEQ ID NO: 27) and QLTPHTKAV (SEQ ID NO: 29). The present invention also provides methods of treating or preventing EBV infection in subjects which involve administration of EBV cytotoxic T-cell epitopes. |
